Novo Nordisk sinks 13% after weight loss drug fails to match Eli Lilly's in trial

Novo Nordisk stock fell 13% Monday after it said its next-generation weight loss drug didn't meet its primary target.

🔗 Read more: https://www.cnbc.com/2026/02/23/novo-nordisk-stock-cagrisema-trial-fails-weight-loss.html

#News #Finance #Biology #Medicine #Business